Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Sep 1;47(9):1269-1270.
doi: 10.1097/DSS.0000000000003096.

Sorafenib-Related Basal Cell Carcinoma

Kodai Miyamoto  1 , Shinya Kitamura, Takuya Maeda, Teruki Yanagi
Affiliations
Case Reports

Sorafenib-Related Basal Cell Carcinoma

Kodai Miyamoto et al. Dermatol Surg. .
No abstract available

PubMed Disclaimer

References

    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
    1. Julien A, Bernard E, Janine W, Alain S, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermal 2008;144:886–92.
    1. Arnault JP, Wechsler J, Escudier B, Spatz A, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59–61.
    1. Breaker K, Naam M, La Rosa FG, Flaig IP, et al. Skin cancer associated with the use of sorafenib for renal cell carcinoma. Dermatol Surg 2013;39:981–7.
    1. Degen A, Satzger I, Voelker B, Kapp A, et al. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology 2010;221:193–6.

Publication types

MeSH terms

LinkOut - more resources